[go: up one dir, main page]

HK1076598A1 - Substituted quinazoline derivatives as inhibitors of aurora kinases - Google Patents

Substituted quinazoline derivatives as inhibitors of aurora kinases

Info

Publication number
HK1076598A1
HK1076598A1 HK05108559.1A HK05108559A HK1076598A1 HK 1076598 A1 HK1076598 A1 HK 1076598A1 HK 05108559 A HK05108559 A HK 05108559A HK 1076598 A1 HK1076598 A1 HK 1076598A1
Authority
HK
Hong Kong
Prior art keywords
inhibitors
quinazoline derivatives
aurora kinases
substituted quinazoline
substituted
Prior art date
Application number
HK05108559.1A
Other languages
English (en)
Inventor
Frederic Henri Jung
Georges Rene Pasquet
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of HK1076598A1 publication Critical patent/HK1076598A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK05108559.1A 2001-12-24 2005-09-28 Substituted quinazoline derivatives as inhibitors of aurora kinases HK1076598A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01403357 2001-12-24
PCT/GB2002/005845 WO2003055491A1 (en) 2001-12-24 2002-12-20 Substituted quinazoline derivatives as inhibitors of aurora kinases

Publications (1)

Publication Number Publication Date
HK1076598A1 true HK1076598A1 (en) 2006-01-20

Family

ID=8183051

Family Applications (1)

Application Number Title Priority Date Filing Date
HK05108559.1A HK1076598A1 (en) 2001-12-24 2005-09-28 Substituted quinazoline derivatives as inhibitors of aurora kinases

Country Status (32)

Country Link
US (2) US7402585B2 (is)
EP (1) EP1463506B1 (is)
JP (1) JP4498741B2 (is)
KR (1) KR101029281B1 (is)
CN (1) CN100491372C (is)
AR (1) AR038052A1 (is)
AT (1) ATE446093T1 (is)
AU (1) AU2002353196B2 (is)
BR (1) BRPI0215312B8 (is)
CA (1) CA2471577C (is)
CY (1) CY1109681T1 (is)
DE (1) DE60234125D1 (is)
DK (1) DK1463506T3 (is)
ES (1) ES2333702T3 (is)
HK (1) HK1076598A1 (is)
HU (1) HU229477B1 (is)
IL (1) IL162541A0 (is)
IS (1) IS2758B (is)
MX (1) MXPA04006260A (is)
MY (1) MY141739A (is)
NO (1) NO328159B1 (is)
NZ (1) NZ533440A (is)
PL (1) PL211694B1 (is)
PT (1) PT1463506E (is)
RU (1) RU2323215C2 (is)
SA (1) SA03230531B1 (is)
SI (1) SI1463506T1 (is)
TW (1) TWI335818B (is)
UA (1) UA82058C2 (is)
UY (1) UY27604A1 (is)
WO (1) WO2003055491A1 (is)
ZA (1) ZA200404923B (is)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002217999A1 (en) 2000-11-01 2002-05-15 Cor Therapeutics, Inc. Process for the production of 4-quinazolinylpiperazin-1-carboxylic acid phenylamides
ATE446093T1 (de) * 2001-12-24 2009-11-15 Astrazeneca Ab Substituierte chinazolin-derivate als aurora- kinase inhibitoren
AU2003249212C1 (en) 2002-07-15 2011-10-27 Symphony Evolution, Inc. Receptor-type kinase modulators and methods of use
DE60328735D1 (de) 2002-12-24 2009-09-17 Astrazeneca Ab Chinazolinderivate
CL2004000797A1 (es) * 2003-04-16 2005-05-27 Astrazeneca Ab Compuestos derivados de quinazolina, inhibidores de aurora quinasa; procedimiento de preparacion; composicion farmaceutica; y su uso para preparar un medicamento para tratar cancer colorrectal, de mama, de pulmon, de prostata, de vejiga, renal o panc
JP2006526599A (ja) * 2003-06-02 2006-11-24 アストラゼネカ アクチボラグ 癌のような増殖性疾患の治療のためのオーロラキナーゼインヒビターとしての（３−（（キナゾリン−４−イル）アミノ）−１ｈ−ピラゾール−１−イル）アセトアミド誘導体及び関連化合物
TW200505452A (en) * 2003-06-17 2005-02-16 Astrazeneca Ab Chemical compounds
US20060178318A1 (en) * 2003-07-03 2006-08-10 Shubha Anand Use of aurora kinase inhibitors for reducing the resistance of cancer cells
CN102432552B (zh) * 2003-08-14 2016-01-20 阿雷生物药品公司 作为受体酪氨酸激酶抑制剂的喹唑啉类似物
SI2392564T1 (sl) 2003-09-26 2014-02-28 Exelixis, Inc. c-Met modulatorji in postopki uporabe
DE602004022318D1 (de) 2003-10-14 2009-09-10 Supergen Inc Proteinkinaseinhibitoren
US20090099165A1 (en) 2003-10-14 2009-04-16 Arizona Board Of Regents On Behalf Of The University Of Arizona Protein Kinase Inhibitors
JP2007514759A (ja) 2003-12-19 2007-06-07 タケダ サン ディエゴ インコーポレイテッド キナーゼ阻害剤
EP1763524A1 (en) * 2004-04-23 2007-03-21 Takeda San Diego, Inc. Indole derivatives and use thereof as kinase inhibitors
BRPI0510604B8 (pt) 2004-05-06 2021-05-25 Warner Lambert Co composto 4-fenilamino-quinazolin-6-il-amida, seu uso e composição farmacêutica que o compreende composto 4-fenilamino-quinazolin-6-il-amida, seu uso e composição farmacêutica que o compreende
BRPI0513405A (pt) * 2004-07-16 2008-05-06 Sunesis Pharmaceuticals Inc tienopirimidinas úteis como inibidores de aurora quinase
US7550598B2 (en) * 2004-08-18 2009-06-23 Takeda Pharmaceutical Company Limited Kinase inhibitors
TW200624431A (en) * 2004-09-24 2006-07-16 Hoffmann La Roche Phthalazinone derivatives, their manufacture and use as pharmaceutical agents
JP4237242B2 (ja) 2004-10-12 2009-03-11 アストラゼネカ アクチボラグ キナゾリン誘導体
DE602005023333D1 (de) * 2004-10-15 2010-10-14 Takeda Pharmaceutical Kinaseinhibitoren
US8153630B2 (en) 2004-11-17 2012-04-10 Miikana Therapeutics, Inc. Kinase inhibitors
GB0427917D0 (en) * 2004-12-21 2005-01-26 Astrazeneca Ab Chemical compounds
JP5075624B2 (ja) 2005-04-28 2012-11-21 田辺三菱製薬株式会社 シアノピリジン誘導体及びその医薬としての用途
GB0510963D0 (en) * 2005-05-28 2005-07-06 Astrazeneca Ab Chemical compounds
WO2007013964A1 (en) * 2005-07-22 2007-02-01 Sunesis Pharmaceuticals, Inc. Pyrazolo pyrimidines useful as aurora kinase inhibitors
CA2622352C (en) * 2005-09-30 2014-05-27 Miikana Therapeutics, Inc. Substituted pyrazole compounds
US8119655B2 (en) * 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
GB0601215D0 (en) * 2006-01-21 2006-03-01 Astrazeneca Ab Chemical compounds
US7560551B2 (en) 2006-01-23 2009-07-14 Amgen Inc. Aurora kinase modulators and method of use
AU2007208351C1 (en) 2006-01-23 2011-07-07 Amgen Inc. Aurora kinase modulators and method of use
US7868177B2 (en) 2006-02-24 2011-01-11 Amgen Inc. Multi-cyclic compounds and method of use
EP1994024A2 (en) * 2006-03-02 2008-11-26 AstraZeneca AB Quinoline derivatives
UY30183A1 (es) * 2006-03-02 2007-10-31 Astrazeneca Ab Derivados de quinolina
EP1998777A1 (en) 2006-03-20 2008-12-10 F. Hoffmann-La Roche AG Methods of inhibiting btk and syk protein kinases
MX2008011769A (es) * 2006-03-20 2008-09-25 Hoffmann La Roche Derivados de ftalazinona pirazol, su fabricacion y uso como agentes farmaceuticos.
GB0609621D0 (en) * 2006-05-16 2006-06-21 Astrazeneca Ab Novel co-crystal
GB0609617D0 (en) 2006-05-16 2006-06-21 Astrazeneca Ab Process & intermediate
CA2652634A1 (en) * 2006-05-18 2007-11-29 Amphora Discovery Corporation Certain substituted quinolones, compositions, and uses thereof
GB0619342D0 (en) * 2006-09-30 2006-11-08 Vernalis R&D Ltd New chemical compounds
CA2664356A1 (en) 2006-10-05 2008-04-10 Banyu Pharmaceutical Co., Ltd. Gene/protein marker for prediction or diagnosis of pharmacological efficacy of aurora a inhibitor
EA200970361A1 (ru) 2006-10-09 2010-02-26 Такеда Фармасьютикал Компани Лимитед Ингибиторы киназы
EP2223925A1 (en) * 2006-10-09 2010-09-01 Takeda Pharmaceutical Company Limited Kinase inhibitors
ES2470341T3 (es) 2007-04-05 2014-06-23 Amgen, Inc Moduladores de la aurora cinasa y método de uso
WO2008154026A1 (en) * 2007-06-11 2008-12-18 Miikana Therapeutics, Inc. Substituted pyrazole compounds
EP2167497A2 (en) * 2007-06-29 2010-03-31 Sunesis Pharmaceuticals, Inc. Heterocyclic compounds useful as raf kinase inhibitors
WO2009111028A1 (en) 2008-03-04 2009-09-11 Vitae Pharmaceuticals, Inc. Aurora kinase inhibitors
CA2716856C (en) 2008-03-20 2013-02-19 Amgen Inc. Aurora kinase modulators and method of use
US9126935B2 (en) 2008-08-14 2015-09-08 Amgen Inc. Aurora kinase modulators and methods of use
CN110818633A (zh) 2009-01-16 2020-02-21 埃克塞里艾克西斯公司 一种苹果酸盐及其晶型
ES2527940T3 (es) * 2009-02-11 2015-02-02 Merck Patent Gmbh Nuevas carboxamidas amino-azaheterocíclicas
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
GB201020179D0 (en) 2010-11-29 2011-01-12 Astex Therapeutics Ltd New compounds
EP2465842A1 (de) * 2010-12-17 2012-06-20 Sika Technology AG Amine mit sekundären aliphatischen Aminogruppen
EA023998B1 (ru) 2011-03-04 2016-08-31 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Аминохинолины в качестве ингибиторов киназ
TWI547494B (zh) 2011-08-18 2016-09-01 葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之胺基喹唑啉類
GB201118675D0 (en) 2011-10-28 2011-12-14 Astex Therapeutics Ltd New compounds
GB201118652D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118656D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118654D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
AR092809A1 (es) 2012-03-16 2015-05-06 Axikin Pharmaceuticals Inc 3,5-diaminopirazol como inhibidor de quinasa
CN104024246B (zh) * 2012-03-27 2016-03-02 广东东阳光药业有限公司 作为欧若拉激酶抑制剂的取代嘧啶衍生物
GB201209613D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
GB201209609D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
TW201425307A (zh) 2012-09-13 2014-07-01 Glaxosmithkline Llc 作為激酶抑制劑之胺基－喹啉類
TWI592417B (zh) 2012-09-13 2017-07-21 葛蘭素史克智慧財產發展有限公司 胺基喹唑啉激酶抑制劑之前藥
JP6301374B2 (ja) * 2013-02-21 2018-03-28 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ キナーゼ阻害剤としてのキナゾリン類
CN104098551B (zh) * 2013-04-03 2019-03-22 广东东阳光药业有限公司 作为欧若拉激酶抑制剂的取代喹唑啉类衍生物
GB201307577D0 (en) 2013-04-26 2013-06-12 Astex Therapeutics Ltd New compounds
SI3046584T1 (sl) 2013-09-16 2017-10-30 Astrazeneca Ab Terapevtski polimerni nanodelci in postopek njihove izdelave in uporabe
NZ631142A (en) 2013-09-18 2016-03-31 Axikin Pharmaceuticals Inc Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
US9771333B2 (en) 2013-11-20 2017-09-26 Signalchem Lifesciences Corp. Quinazoline derivatives as TAM family kinase inhibitors
JO3512B1 (ar) 2014-03-26 2020-07-05 Astex Therapeutics Ltd مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
US10736900B2 (en) 2014-03-26 2020-08-11 Astex Therapeutics Ltd Combinations of an FGFR inhibitor and an IGF1R inhibitor
MA39784B1 (fr) 2014-03-26 2021-03-31 Astex Therapeutics Ltd Combinaisons des inhibiteurs du fgfr et du cmet destinées au traitement du cancer
EA032473B1 (ru) 2014-12-23 2019-05-31 Аксикин Фармасьютикалз, Инк. 3,5-диаминопиразоловые ингибиторы киназы
JOP20200201A1 (ar) 2015-02-10 2017-06-16 Astex Therapeutics Ltd تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
EP3353177B1 (en) 2015-09-23 2020-06-03 Janssen Pharmaceutica NV Tricyclic heterocycles for the treatment of cancer
SI3353164T1 (sl) 2015-09-23 2022-02-28 Janssen Pharmaceutica, N.V. Bi-heteroaril substituiran 1,4-benzodiazepini in njihove uporabe za zdravljenje raka
CN112939948B (zh) * 2019-12-11 2022-05-17 苏州美诺医药科技有限公司 新型含喹唑啉类化合物及其中间体与应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL89029A (en) 1988-01-29 1993-01-31 Lilly Co Eli Fungicidal quinoline and cinnoline derivatives, compositions containing them, and fungicidal methods of using them
ES2108120T3 (es) 1991-05-10 1997-12-16 Rhone Poulenc Rorer Int Compuestos bis arilicos y heteroarilicos mono- y biciclicos que inhiben tirosina quinasa receptora de egf y/o pdgf.
US5721237A (en) * 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
US5710158A (en) 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5480883A (en) * 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
GB9510757D0 (en) 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
TW321649B (is) 1994-11-12 1997-12-01 Zeneca Ltd
GB9514265D0 (en) 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
ZA986732B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
ES2241324T3 (es) * 1998-10-08 2005-10-16 Astrazeneca Ab Derivados de quinazolina.
CA2384291A1 (en) * 1999-09-21 2001-03-29 Astrazeneca Ab Quinazoline derivatives and their use as pharmaceuticals
GB9922171D0 (en) * 1999-09-21 1999-11-17 Zeneca Ltd Chemical compounds
GB0006864D0 (en) * 2000-03-21 2000-05-10 Smithkline Beecham Plc New use
DE60133897D1 (de) 2000-06-28 2008-06-19 Astrazeneca Ab Substituierte chinazolin-derivate und deren verwendung als aurora-2-kinase inhibitoren
US6610677B2 (en) * 2000-09-15 2003-08-26 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
GB0124299D0 (en) * 2001-10-10 2001-11-28 Astrazeneca Ab Crystal structure of enzyme and uses thereof
ATE446093T1 (de) * 2001-12-24 2009-11-15 Astrazeneca Ab Substituierte chinazolin-derivate als aurora- kinase inhibitoren
US7105425B1 (en) * 2002-05-16 2006-09-12 Advanced Micro Devices, Inc. Single electron devices formed by laser thermal annealing
DE60328735D1 (de) * 2002-12-24 2009-09-17 Astrazeneca Ab Chinazolinderivate
CL2004000797A1 (es) * 2003-04-16 2005-05-27 Astrazeneca Ab Compuestos derivados de quinazolina, inhibidores de aurora quinasa; procedimiento de preparacion; composicion farmaceutica; y su uso para preparar un medicamento para tratar cancer colorrectal, de mama, de pulmon, de prostata, de vejiga, renal o panc
JP2006526599A (ja) * 2003-06-02 2006-11-24 アストラゼネカ アクチボラグ 癌のような増殖性疾患の治療のためのオーロラキナーゼインヒビターとしての（３−（（キナゾリン−４−イル）アミノ）−１ｈ−ピラゾール−１−イル）アセトアミド誘導体及び関連化合物
WO2006040526A1 (en) * 2004-10-12 2006-04-20 Astrazeneca Ab Quinazoline derivatives for use against cancer
GB0427917D0 (en) * 2004-12-21 2005-01-26 Astrazeneca Ab Chemical compounds
JP2008542345A (ja) * 2005-05-28 2008-11-27 アストラゼネカ アクチボラグ キナゾリン類及びオーロラキナーゼ阻害剤としてのその使用
GB0601215D0 (en) * 2006-01-21 2006-03-01 Astrazeneca Ab Chemical compounds
GB0609621D0 (en) * 2006-05-16 2006-06-21 Astrazeneca Ab Novel co-crystal
GB0609619D0 (en) * 2006-05-16 2006-06-21 Astrazeneca Ab Combination
GB0609617D0 (en) * 2006-05-16 2006-06-21 Astrazeneca Ab Process & intermediate
CN101896227A (zh) * 2007-12-12 2010-11-24 阿斯利康(瑞典)有限公司 包含mek抑制剂和极光激酶抑制剂的组合

Also Published As

Publication number Publication date
BRPI0215312B8 (pt) 2021-05-25
DE60234125D1 (de) 2009-12-03
HUP0402454A2 (hu) 2005-03-29
NO328159B1 (no) 2009-12-21
HU229477B1 (en) 2014-01-28
KR20040066929A (ko) 2004-07-27
WO2003055491A1 (en) 2003-07-10
BR0215312A (pt) 2004-12-07
UY27604A1 (es) 2003-07-31
CA2471577A1 (en) 2003-07-10
US7402585B2 (en) 2008-07-22
DK1463506T3 (da) 2010-01-11
BRPI0215312B1 (pt) 2018-03-27
PT1463506E (pt) 2009-12-10
CA2471577C (en) 2011-08-02
ATE446093T1 (de) 2009-11-15
HUP0402454A3 (en) 2009-08-28
EP1463506B1 (en) 2009-10-21
ES2333702T3 (es) 2010-02-26
SI1463506T1 (sl) 2010-01-29
RU2004122926A (ru) 2005-07-10
PL211694B1 (pl) 2012-06-29
CY1109681T1 (el) 2014-08-13
TW200410697A (en) 2004-07-01
PL371253A1 (en) 2005-06-13
NO20043158L (no) 2004-09-16
SA03230531B1 (ar) 2008-09-08
SA03230531A (ar) 2005-12-03
ZA200404923B (en) 2005-11-30
JP2005525307A (ja) 2005-08-25
UA82058C2 (uk) 2008-03-11
RU2323215C2 (ru) 2008-04-27
US20050070561A1 (en) 2005-03-31
AU2002353196A1 (en) 2003-07-15
JP4498741B2 (ja) 2010-07-07
IL162541A0 (en) 2005-11-20
CN1620296A (zh) 2005-05-25
CN100491372C (zh) 2009-05-27
EP1463506A1 (en) 2004-10-06
MXPA04006260A (es) 2005-03-31
AU2002353196B2 (en) 2008-01-17
US20090215770A1 (en) 2009-08-27
IS7328A (is) 2004-06-21
AR038052A1 (es) 2004-12-22
MY141739A (en) 2010-06-15
NZ533440A (en) 2006-08-31
IS2758B (is) 2011-10-15
KR101029281B1 (ko) 2011-04-18
TWI335818B (en) 2011-01-11

Similar Documents

Publication Publication Date Title
IL162541A0 (en) Substituted quinazoline derivatives as inhibitors of aurora kinases
HK1160859A1 (en) Inhibitors of tyrosine kinases
EP1363702A4 (en) PROCESS FOR INHIBITING KINASES
HK1072545A1 (en) Novel inhibitors of kinases
HK1091480A1 (en) Quinazoline derivatives as tyrosine kinase inhibitors
IL174258A0 (en) Quinazoline derivatives as tyrosine kinase inhibitors
AU2003251559A8 (en) Heterocyclic inhibitors of kinases
AU2003233455A1 (en) Novel fused quinazoline derivatives useful as tyrosine kinase inhibitors
IL172375A0 (en) Chinazoline derivatives as aurora kinase inhibitors
EP1390052A4 (en) INHIBITION OF JUN KINASE
IL157442A0 (en) Cyano substituted dihydropyrimidine derivatives
HUP0401641A3 (en) Use of substituted diazonine derivatives as phosphorodiesterase iv inhibitors
HK1079195A1 (en) Quinazoline derivatives as src tyrosine kinase inhibitors
AU2003268464A8 (en) Indole-type derivatives as inhibitors of p38 kinase
MXPA03006423A (es) Naftostirilos.
ZA200500492B (en) Novel inhibitors of kinases
AU2002255130A1 (en) Isoquinolinone derivatives as parp inhibitors
AU2002307475A1 (en) Inhibition of jun kinase

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20221215